To further explore, Jiao and colleagues compared mice models with bone mCRPC versus subcutaneous mCRPC and found anti-CTLA-4/anti-PD-1 antibodies had minimal effects on tumor volume and OS in mice bearing the bone CRPC lesions but significant regression and improved OS in the mice with subcutaneous CRPC [42]. This evidence concerns the gene PDCD1 and neoplasm.